Abstract: Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

Abstract: Described herein are compositions and methods for the prevention or treatment of rheumatoid arthritis (RA). In some embodiments, RA is prevented or treated by (i) extracting peripheral blood mononuclear cells (PBMCs) and/or bone marrow mononuclear cells (BMMCs) from a subject at risk of, or afflicted with, RA; (ii) exposing the PBMCs/BMMCs to an effective amount of one or more SHIP-1 inhibitor and/or a pan-SHIP1/2 inhibitor to induce ex vivo expansion of the subject's myeloid derived suppressor cells (MDSCs); and (iii) administering intravenously to the subject a therapeutically effective number of MDSCs.

Abstract: The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.

Abstract: The present invention relates to a human macrophage for use in cancer therapy, said human macrophage comprising at least one mutation in both alleles of a chromosomal gene, wherein said macrophage is resistant to tumor-induced reprogramming and/or shows anti-tumor activity. The human macrophage of the invention demonstrates typical markers of an M1 macrophage, such as the presence of MHC class II proteins, even after having been cultured in an environment which promotes M2-polarization, such as in the presence of M-CSF and/or IL4 and/or IL13. The invention also relates to a collection of human macrophages of the invention, to their use in medicine, and in particular to their use in cancer therapy such as the treatment of solid tumors as a preferred example.

Abstract: Provided herein are, among other things, methods for treating a patient suffering from a HER2+ cancer.

Abstract: Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to suppress alloreactive donor cells. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed regulatory T cells engineered to express the disclosed CARs. Also disclosed is a method of preventing rejection of off-the-shelf therapeutic immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject an effective amount of a regulatory T cell genetically modified with a disclosed CD83-specific CAR.

Abstract: Disclosed herein is a chimeric antigen receptor (CAR) comprising a single-chain variable fragment specific to Globo H, a hinge and transmembrane domain, a co-stimulatory molecule, and a cytoplasmic domain. According to some embodiments of the present disclosure, the CAR further comprises a single-chain variable fragment specific to PD-L1, and optionally, a fragment crystallizable region of an immunoglobulin. Also disclosed herein are isolated nucleic acids encoding the CAR pharmaceutical kits comprising the isolated immune cells expressing the CAR, and methods of treating cancers by using isolated immune cells.

Abstract: The present invention relates to a composition comprising a supernatant of a peripheral blood mononuclear cell (PBMC) cell culture for use in the treatment of skin scars.

Abstract: Aspects of the present disclosure relate to methods and compositions for genetic modification of immune cells to generate immune cells that do not secrete TGF-?1. Also disclosed are methods for use of such genetically modified immune cells, including immunotherapeutic methods for the treatment of cancer. Further aspects of the disclosure are directed to human CD8+ cells comprising a genetic modification that prevents the cells from secreting TGF-?1.

Abstract: Provided herein are methods for treatment and uses involving dosing of compositions containing NK cells. Among the provided methods and uses are methods and uses for treating cancer, such as multiple myeloma or lymphoma, including in combination with an antibody therapeutic for the cancer.

Abstract: The disclosure provides methods and compositions for treating glioblastoma (GBM) using a 5T4-targeting agent, e.g., a superantigen conjugate comprising an anti-5T4 antibody.

Abstract: The present invention provides methods for isolating and cryopreserving tumor infiltrating lymphocytes (TILs) and producing therapeutic populations of TILs, including methods via use of a kit and a semi-automatic device for aseptic disaggregation, enrichment, and cryopreservation of a resected tumor prior to expansion of the TIL population. The present invention also provides methods for expansion, and/or stabilization of TILs, for instance UTILs, compositions involving the same and methods of treatment involving the same.

Abstract: Compositions and methods are presented that include exosomes from stem cells and/or tumor cells that were previously exposed to an inflammatory stimulus. Advantageously, such exosomes exhibit anti-inflammatory and analgesic effect when administered to an individual. Therefore, a preferred use of such exosomes will reduce the need for opioid analgesics, and reduce pain and inflammation.

Abstract: The present disclosure relates to methods for treating or preventing Acute Respiratory Distress Syndrome (ARDS) in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).

Abstract: A pharmaceutical composition utilizes a cultured product obtained by differentiating a mesenchymal stem cell into a neuron. The pharmaceutical composition may be used to treat Parkinson's disease. The cultured product exhibits a preventive or therapeutic effect against Parkinson's disease by inhibiting dopaminergic neuron apoptosis by reducing insoluble alpha-synuclein aggregated in the neuron.

Abstract: Disclosed herein are methods of treating Canavan disease in a subject through restoring ASPA enzymatic activities in the subject by expressing exogenous wild type ASPA gene in the brain of the subject. Also disclosed are a process of producing neural precursor cells, including NPCs, glial progenitor cells and oligodendroglial progenitor cells, which express an exogenous wild type ASPA gene and the neural precursor cells produced by this process.

Abstract: The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle.

Abstract: The present invention relates to a composition comprising vascular endothelial progenitor cells and mesenchymal stem cells as active ingredients for prevention or treatment of occlusive vascular diseases or complications thereof. Since it was found that vascular endothelial progenitor cells and mesenchymal stem cells remarkably improved vascularization ability upon application thereof in combination, the present invention has the effect of providing a new cell therapy product for prevention or treatment of occlusive vascular diseases or ulcers resulting therefrom, and a preparation method therefore.

Abstract: An efficient and scarless gene editing system for Salmonella and the use thereof are provided. ?Red recombinase is used to promote a double crossover of a DNA template with a genomic target site, the CRISPR/Cas9 system is used for screening, and one-step homologous recombination is used to rapidly construct a targeting plasmid, which can realize insertion, substitution or knock-out of genes. Genomic DNA is completely substituted according to a design of homologous template, and without other fragment residues. Genome editing can be completed efficiently within 3-4 days, thereby reducing the experimental workload and shortening the experimental cycle.

Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.

Abstract: The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-including bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-including composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment.

Abstract: Described herein are methods of identifying, characterizing, and treating depression and anxiety in a subject by modulating indoles associated with tryptophan metabolism in the subject and subject's gut microbiome.

Abstract: The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

Abstract: The present invention provides a pharmaceutical composition comprising a probiotic and a prebiotic for preventing acquisition of and/or alleviating symptoms associated with an infection caused by an Extended-spectrum beta-lactamases (ESBL) producing organism and other drug resistant pathogens. More particularly, the pharmaceutical composition comprises at least one Lactillobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of preventing acquisition of and/or treating an infection caused by Extended-spectrum beta-lactamases (ESBL) producing bacteria and other drug resistant pathogens, comprising administering an effective amount of a pharmaceutical composition comprising a probiotic and a prebiotic to a subject in need thereof.

Abstract: The present invention provides a method of increasing mental well-being and/or happiness in a subject comprising administering an effective amount of a bacteria or a component thereof to a subject. The present invention also provides use of a bacteria or a component thereof in the manufacture of a medicament for increasing mental well-being and/or happiness in a subject and a composition comprising a bacteria or a component thereof for use in increasing mental well-being and/or happiness in a subject.

Abstract: Ganoderma lucidum spore oil and use thereof in the preparation of anti-cancer-related fatigue medicaments are provided. The content of triglycerides in the Ganoderma lucidum spore oil is greater than 90%. Ganoderma lucidum triterpenoids are not detected. The Ganoderma lucidum spore oil is extracted by means of supercritical CO2, eluted with a silica gel column and a mixed solution of petroleum ether-ethyl acetate, concentrated under reduced pressure and vacuum-dried. The Ganoderma lucidum spore oil is highly effective in mitigating cancer-related fatigue, has good safety, and can be used in the preparation of medicaments for treating cancer-related fatigue.

Abstract: This invention provides for a prophylactic and therapeutic natural and safe agent, which contains Aristotelia chilensis berry extract as an active substance or extracts of other berries, for the prevention and treatment of fungal candidiasis infections in the digestive, urogenital tract but also in systemic diseases caused by fungi of the genus Candida especially Candida albicans, by the mechanism of filamentation inhibition. Other berries can be from the group of chokeberry, cranberry, blueberry, currant or other berry fruit.

Abstract: This disclosure relates to administering, manufacturing, and composing oral formulations to treat and prevent fatty liver disease, liver dysfunction, and hepatic impairment. The treatment and prevention may be one or both liver dysfunction-related primary and secondary diseases. The herbal blend may be made of one or more artichokes, dandelion, milk thistle, alpha-lipoic acid, and turmeric. The enzyme blend may be made of one or more isolated enzymes from amylase, glucoamylase, protease 4.5, protease 6, protease 3, neutral protease, peptidase, papain, alpha-galactosidase, acid maltase, cellulase, pectinase, protease inhibitor 6.0, lipase, lactase, bromelain, cellulase, xylanase, beta-glucanase, invertase, hemicellulose, etc., and any combination thereof. The formulation may be in two compartments, the outer and the inner—the outer compartment has the herbal blend and the internal has the enzyme blend. The inner compartment may be gastric acid resistant.

Abstract: A use of a Crassocephalum rabens extract in detoxification is disclosed. The Crassocephalum rabens extract has the activity to remove such substances in an organism or the cells thereof as a heavy metal, so the administration of an effective amount of the Crassocephalum rabens extract or of a composition containing the Crassocephalum rabens extract to an individual can effectively reduce the heavy metal content in the individual's body and help restore the individual's liver functions.

Abstract: A method for treating psoriasis is provided, including administering a pharmaceutical composition to a subject suffering from psoriasis, wherein the pharmaceutical composition comprises an effective amount of mangosteen fruit shell extract, the mangosteen fruit shell is outer shell of the mangosteen fruit shell and/or inner shell of the mangosteen fruit shell, and the pharmaceutical composition is an external preparation.

Abstract: The present invention relates to the pharmaceutical and nutraceutical fields and, more specifically, to a composition comprising an extract from a combination of plants for the prevention and/or treatment of a neurodegenerative disease

Abstract: The present invention provides a composite for relieving functional dyspepsia, a preparation method therefor, a use thereof, a drug, a food and a health-care product. The composite comprises the following components in parts by weight: 2 to 8 parts of dried orange peels, 1 to 6 parts of figs, and 1 to 5 parts of seville orange flowers. The composite of the present invention is prepared from medicinally and edibly homologous natural plant raw materials, which has good safety without side effects, and can be used to treat and/or prevent functional dyspepsia. The composite can also be used to prevent depression and improve sleep, with significant, mild and gradual curative effects, so as to provide a patient with daily health care and drug security.

Abstract: The present disclosure provides a method of preparing an ebelin lactone or bacogenin A1 enriched composition from acid-hydrolyzed extract of Bacopa monnieri. Also provided is a composition prepared by the method. Advantageously, the present method may yield a cost effective product containing at least 10% ebelin lactone, which may result in an entirely new subjective experience with fully hydrolyzed Bacopa monnieri extract.

Abstract: The present application relates to water-soluble formulations. More specifically, the present application relates to formulations comprising at least one of Coenzyme-Q10 and an ashwagandha root extract and a solubilizing agent. More specifically, the present application relates to formulations comprising water-solubilized Coenzyme-Q10 in combination with alcohol-extracted ashwagandha root extract; water-solubilized alcohol-extracted ashwagandha root extract; or water-solubilized Coenzyme-Q10 in combination with water-solubilized alcohol-extracted ashwagandha root extract. The formulations of the present application are useful for treating reducing or preventing a neurological diseases or disorders.

Abstract: Compositions and methods for mitigating and preventing the effects of alcohol consumption are provided. A first composition can be ingested by an individual prior to or within six hours of alcohol consumption. A second composition can be ingested by the individual either at the onset of negative symptoms associated with alcohol consumption or the morning following alcohol consumption. The first and second compositions can be ingested individually, or in combination. When both the first and second composition are consumed, the first composition is to be consumed prior to the second composition, and both are to be consumed in a timely manner. Both compositions can be administered orally. The compositions can each be administered as a fluid solution. Only one serving of each composition is required to achieve the desired effects. Results are strengthened when both compositions are consumed in combination.

Abstract: A method for hair care is provided, including administering a composition to a subject in need thereof. The composition includes an effective amount of banana flower extract and a carrier, where the banana flower extract is compound I shown in formula (I) below, compound II shown in formula (II) below, or a combination thereof: The banana flower extract can be used for increasing hair root diameter sizes, enhancing hair follicle robustness, reducing hair loss, inhibiting dihydrotestosterone (DHT) generation, promoting hair growth, and increasing hair follicle cell proliferation.

Abstract: The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers.

Abstract: A method of increasing antimicrobial peptide concentration on the skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more polypeptides and natural extracts that increase the concentration of antimicrobial peptides.

Abstract: Disclosed are methods of treating cardiac injury in a subject comprising administering a therapeutically effective amount of angiotensin II to the subject. Also disclosed are methods of treating catecholamine-associated cardiac injury in a subject comprising administering a therapeutically effective amount of angiotensin II to the subject. The subject can have cardiac injury, or the subject can be at risk of having cardiac injury.

Abstract: The invention relates to an oxytocin receptor agonist for use in the treatment or prevention of dysphagia in a subject suffering from an autonomic nervous system dysfunction.

Abstract: This disclosure is related to the use of a peptide with antimicrobial properties. The peptide is administered to prevent or treat non-respiratory diseases caused by viruses. A variety of formulations and uses are described as well as methods of manufacture thereof. The formulations are safe and useful in patients—both humans and animals—for the delivery of appropriate bioactive substance(s).

Abstract: Provided herein are methods and compositions for improving visual function in an eye of an individual having an ocular disorder. The methods described herein generally comprise methods of improving visual function (e.g., BCVA) in an eye of an individual having an ocular disease or disorder, comprising: administering a peptide (e.g., a composition comprising the peptide) comprising an amino acid sequence HHIYLGAVNYIY or a variant sequence thereof, or a pharmaceutically-acceptable salt of the peptide, to the eye of the individual.

Abstract: A treatment of rejection of a transplant by a recipient of the transplant is disclosed. Methods for prolonging transplant survival in a recipient of the transplant, prolonging survival of the recipient, delaying and/or suppressing delayed graft function in the recipient, and/or reducing the amount of an immunosuppressant administered for transplantation. The methods include providing the transplant with a CHP or a pharmaceutically acceptable salt thereof is disclosed. Also provided is a method for the production of a pharmaceutical composition for the treatment of a transplant allowing modulating transplant survival in a recipient of the transplant.

Abstract: Provided herein are compositions and methods for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions. Specifically. the disclosure provides a method of treating an alloimmune, autoimmune, inflammatory, or mitochondrial condition in a subject, the method comprising: administering a calcineurin inhibitor and a cytochrome p450 inhibitor, wherein calcineurin inhibitor comprising cyclosporine, tacrolimus, pimecrolimus, or analogs or derivatives thereof. Further disclosed are cytochrome p450 inhibitors that can be used for the method.

Abstract: Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.

Abstract: This document provides methods and materials for treating a mammal having Alzheimer's disease (AD). For example, one or more Zika virus (ZIKV) polypeptides can be administered to a mammal having, or at risk of developing, AD to treat the mammal.

Abstract: Described herein are bacteriocin peptides, peptidomimetics, compositions, pharmaceutical compositions, and cosmetic compositions comprising same. Aspects and embodiments described herein may be used in medical treatment, disinfection of surfaces and cosmetics.

Abstract: The present disclosure concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions including the polypeptide, and their use. The disclosure shows that increasing concentration of the hReg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation.

Abstract: The present application relates to extensively hydrolysed protein, and compositions comprising extensively hydrolysed protein, for use in reducing the risk of intestinal inflammation, reducing the risk of intestinal tissue damage, and/or improving gut barrier function, in an infant.

Abstract: Provided herein are compositions comprising an antimicrobial cationic amphipathic polypeptide (PAX) and methods of using the same for treatment of a microbial infection